Pharis Mohideen - Nov 21, 2024 Form 4 Insider Report for DBV Technologies S.A. (DBVT)

Role
Chief Medical Officer
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
DBVT
Transactions as of
Nov 21, 2024
Transactions value $
-$1,269
Form type
4
Date filed
11/25/2024, 05:13 PM
Previous filing
Jul 31, 2024
Next filing
Nov 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBVT Ordinary Shares Award $0 +35K +44.1% $0.00 114K Nov 21, 2024 Direct F1, F2
transaction DBVT Ordinary Shares Sale -$1.27K -2.35K -2.05% $0.54 112K Nov 21, 2024 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DBVT Employee Stock Option (right to buy) Award $0 +215K $0.00 215K Nov 21, 2024 Ordinary Shares 215K $0.75 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share.
F2 Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date.
F3 Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F4 This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024.
F5 The option shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date.